Breaking News Instant updates and real-time market news.

2019-11-04 18:30:26 HCA HCA Healthcare $136.26 2.61 (1.95%) 18:30 11/04/19 11/04 18:30 11/04/19 18:30	HCA Healthcare's Foster sells 19,477 common shares In a regulatory filing, HCA Healthcare group president Jon M. Foster disclosed the sale of 19,477 common shares of the company at a price of $132.3462 on October 31.	06 Nov 13 Nov
HCA HCA Healthcare $136.26 2.61 (1.95%) 07/31/19 MZHO 07/31/19 NO CHANGE Target $153 MZHO Buy HCA Healthcare selloff yesterday an overreaction, says Mizuho Mizuho analyst Ann Hynes views the 9% post-earnings selloff yesterday in shares of HCA Healthcare as an overreaction. Expectations were high for a beat and a meaningful guidance raise going into the Q2 report given the significant outperformance in Q1, and HCA did not meet those expectations, Hynes tells investors in a research note. The analyst, however, does not believe there is any fundamental change to HCA's business. She keeps a Buy rating on the shares with a $153 price target. 09/03/19 EVER 09/03/19 NO CHANGE EVER Evercore says Tenet has highest exposure among hospitals to Dorian's new path Evercore ISI analyst Michael Newshel estimates that Tenet (THC) has 22% of its beds in coastal counties in Florida, Georgia, South Carolina and North Carolina, where mandatory evacuations have been ordered in certain coastal areas due to the expected path of Hurricane Dorian. HCA Healthcare (HCA) has 15% of its beds in coastal counties in Florida, George and South Carolina, including 8% in counties that have received evacuation orders, while Universal Health (UHS) has one acute hospital, representing 3.6% of its total acute beds, in the affected coastal counties, and 8% of its behavioral beds are in coastal counties, the analyst noted. Newshel said Community Health (CYH), Quorum Health (QHC) and Acadia (ACHC) do not have any coastal exposure in the four states expected to be most impacted by Dorian. 09/06/19 BOFA 09/06/19 UPGRADE Target $137 BOFA Neutral HCA Healthcare upgraded to Neutral from Underperform at BofA/Merrill BofA/Merrill analyst Kevin Fischbeck upgraded HCA Healthcare to Neutral, also raising its price target to $137 from $130. The analyst notes that the company missed its Q2 results with EBITDA reported about $100M below consensus, but after a 15% decline in the stock price ahead of the release, he sees the valuation as "priced to perfection" and risk/reward more balanced at 7.5-times his expected 2020 EBITDA. Fischbeck adds that he expects HCA Healthcare to address the sales mix and earnings shortfall of Q2 faster than expected by the Street. 10/30/19 LEHM 10/30/19 NO CHANGE Target $155 LEHM Overweight HCA Healthcare price target raised to $155 from $145 at Barclays Barclays analyst Steve Valiquette raised his price target for HCA Healthcare to $155 from $145 saying the company in Q3 reported a "nice snapback" in commercial surgical volumes and improved same-store revenue per adjusted admission. The analyst believes the company's "strong" operating momentum will continue into 2020 and he keeps an Overweight rating on the shares.

2019-11-04 18:30:26

HCA

HCA Healthcare

$136.26: 2.61 (1.95%)

18:30

11/04/19

11/04

18:30

11/04/19

18:30

HCA Healthcare's Foster sells 19,477 common shares

In a regulatory filing, HCA Healthcare group president Jon M. Foster disclosed the sale of 19,477 common shares of the company at a price of $132.3462 on October 31.

06
Nov
13
Nov

HCA HCA Healthcare

$136.26: 2.61 (1.95%)

07/31/19: MZHO

09/03/19: EVER

09/06/19: BOFA

10/30/19: LEHM

TODAY'S FREE FLY STORIES

FB Facebook $200.99 1.64 (0.82%) , GOOGL Alphabet Class A $1,339.41 11.6 (0.87%) … 09:31 12/07/19 12/07 09:31 12/07/19 09:31 On The Fly	Week in review: How Trump's policies moved stocks » Catch up on the top… Open Full Text FB Facebook $200.99 1.64 (0.82%) GOOGL Alphabet Class A $1,339.41 11.6 (0.87%) GOOG Alphabet $1,341.23 12.23 (0.92%) AAPL Apple $270.71 5.15 (1.94%) AMZN Amazon.com $1,750.79 10.2 (0.59%) SQ Square $68.00 0.85 (1.27%) TWTR Twitter $30.19 0.16 (0.53%) CSIQ Canadian Solar $18.35 0.39 (2.17%) FSLR First Solar $53.36 1.06 (2.03%) JASO JA Solar $0.00 (0.00%) SPWR SunPower $7.23 0.15 (2.12%) TSL Trina Solar $0.00 (0.00%) YGE Yingli Green Energy $0.00 (0.00%) AKS AK Steel $3.24 0.065 (2.05%) MT ArcelorMittal $17.88 0.43 (2.46%) NUE Nucor $57.60 1.13 (2.00%) STLD Steel Dynamics $35.10 0.67 (1.95%) TMST TimkenSteel $6.90 0.41 (6.32%) X U.S. Steel $13.95 0.615 (4.61%) AA Alcoa $20.60 0.68 (3.41%) 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec 10 Dec 06 Feb 26 Feb
FATE Fate Therapeutics $13.64 0.07 (0.52%) 09:27 12/07/19 12/07 09:27 12/07/19 09:27 Hot Stocks	Fate Therapeutics reports initial clinical data for FT516 and FT50 » Fate Therapeutics … Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
09:25 12/07/19 12/07 09:25 12/07/19 09:25 Conference/Events	JPMorgan enterprise software analyst to hold an analyst/industry conference call » Software Analyst Murphy,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
CRVS Corvus Pharmaceuticals $4.26 -0.36 (-7.79%) 09:23 12/07/19 12/07 09:23 12/07/19 09:23 Hot Stocks	Corvus reports initial results from Phase 1/1b trial of CPI-818 » Corvus Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
KPTI Karyopharm $16.30 -1.15 (-6.59%) 09:21 12/07/19 12/07 09:21 12/07/19 09:21 Hot Stocks	Karyopharm announces updated Xpovio data in multiple myeloma » Karyopharm Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec

ABBV AbbVie $86.97 0.3 (0.35%) 09:18 12/07/19 12/07 09:18 12/07/19 09:18 Hot Stocks	AbbVie reports results of 7.5-year pooled analysis of Imbruvica » AbbVie announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
SRRA Sierra Oncology $0.49 0.1035 (27.13%) 09:16 12/07/19 12/07 09:16 12/07/19 09:16 Hot Stocks	Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib » Sierra Oncology reported… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec 08 Dec
SGMO Sangamo $11.65 0.05 (0.43%) , PFE Pfizer $38.29 0.26 (0.68%) 09:14 12/07/19 12/07 09:14 12/07/19 09:14 Hot Stocks	Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study » Sangamo Therapeutics… SGMO Sangamo $11.65 0.05 (0.43%) PFE Pfizer $38.29 0.26 (0.68%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec 09 Dec 11 Dec
VSTM Verastem $1.31 0.055 (4.38%) 09:12 12/07/19 12/07 09:12 12/07/19 09:12 Hot Stocks	Verastem announces 62% response rate for duvelisib in T-cell lymphoma » Verastem announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
RHHBY Roche $0.00 (0.00%) 09:09 12/07/19 12/07 09:09 12/07/19 09:09 Hot Stocks	Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma » Genentech, a member of… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec 09 Dec 10 Dec 10 Dec 16 Dec

XENE Xenon Pharmaceuticals $13.92 0.03 (0.22%) , BMRN BioMarin $79.90 -0.18 (-0.22%) 08:59 12/07/19 12/07 08:59 12/07/19 08:59 Hot Stocks	Xenon to provide updates on partnered epilepsy programs » Xenon Pharmaceuticals… XENE Xenon Pharmaceuticals $13.92 0.03 (0.22%) BMRN BioMarin $79.90 -0.18 (-0.22%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
CLF Cleveland-Cliffs $8.14 0.2 (2.52%) , AKS AK Steel $3.24 0.065 (2.05%) 08:56 12/07/19 12/07 08:56 12/07/19 08:56 Recommendations	Cleveland-Cliffs, AK Steel analyst commentary » Cleveland-Cliffs shares… CLF Cleveland-Cliffs $8.14 0.2 (2.52%) AKS AK Steel $3.24 0.065 (2.05%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
M Macy's $15.15 0.04 (0.26%) 08:53 12/07/19 12/07 08:53 12/07/19 08:53 Periodicals	Barron's skeptical on Macy's shares into the holiday season » The turnaround at… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
COF Capital One $101.39 1.8 (1.81%) 08:43 12/07/19 12/07 08:43 12/07/19 08:43 Periodicals	Capital One shares could have more upside ahead, Barron's says » Shares of Capital One… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	26 Feb
EXPE Expedia $107.58 1.9 (1.80%) 08:26 12/07/19 12/07 08:26 12/07/19 08:26 Periodicals	Expedia shares still a buy despite management changes, Barron's says » Shares of Expedia remain… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	09 Dec

DAR Darling Ingredients $24.05 0.39 (1.65%) , CODI Compass Diversified $23.88 0.45 (1.92%) … 08:21 12/07/19 12/07 08:21 12/07/19 08:21 Periodicals	Darling, Qualys among small-caps to own for 2020 breakout, Barron's says » In its weekend cover… DAR Darling Ingredients $24.05 0.39 (1.65%) CODI Compass Diversified $23.88 0.45 (1.92%) QLYS Qualys $85.37 -0.37 (-0.43%) LECO Lincoln Electric $92.52 0.69 (0.75%) HASI Hannon Armstrong $29.50 0.24 (0.82%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	10 Dec 12 Dec
CBMG Cellular Biomedicine $17.56 0.18 (1.04%) 08:11 12/07/19 12/07 08:11 12/07/19 08:11 Hot Stocks	Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma » Cellular Biomedicine… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
AXLA Axcella $3.63 -0.83 (-18.61%) 08:07 12/07/19 12/07 08:07 12/07/19 08:07 Hot Stocks	Axcella says preclinical of AXA4010 data show multifactorial potential » Axcella Health announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial
AZN AstraZeneca $47.68 0.06 (0.13%) 08:04 12/07/19 12/07 08:04 12/07/19 08:04 Hot Stocks	AstraZeneca says Calquence combination improved survival in leukemia patients » AstraZeneca presented… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec 09 Dec
ABBV AbbVie $86.97 0.3 (0.35%) 08:01 12/07/19 12/07 08:01 12/07/19 08:01 Hot Stocks	AbbVie announces follow-up data from chronic lymphocytic leukemia study » AbbVie announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec

ABBV AbbVie $86.97 0.3 (0.35%) 07:56 12/07/19 12/07 07:56 12/07/19 07:56 Hot Stocks	AbbVie announces data from Phase 2 lymphocytic leukemia study » AbbVie announced new data… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec
JNJ Johnson & Johnson $140.36 0.79 (0.57%) 07:51 12/07/19 12/07 07:51 12/07/19 07:51 Hot Stocks	Janssen announces initial results from Phase 1b/2 multiple myeloma study » Janssen Pharmaceutical… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in in 9 minutes Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec 09 Dec 21 Jan
XBIT XBiotech $11.11 0.1 (0.91%) , JNJ Johnson & Johnson $140.36 0.79 (0.57%) 07:46 12/07/19 12/07 07:46 12/07/19 07:46 Hot Stocks	XBiotech sells bermekimab to Janssen for $750M plus potential milestones » XBiotech (XBIT) announced… XBIT XBiotech $11.11 0.1 (0.91%) JNJ Johnson & Johnson $140.36 0.79 (0.57%) Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Dec 09 Dec 21 Jan
PCG PG&E $9.65 -0.13 (-1.33%) 07:39 12/07/19 12/07 07:39 12/07/19 07:39 Hot Stocks	PG&E to amend and finalize bankruptcy plan following settlement » PG&E said in a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan
PCG PG&E $9.65 -0.13 (-1.33%) 07:39 12/07/19 12/07 07:39 12/07/19 07:39 Hot Stocks	PG&E to amend and finalize bankruptcy plan following settlement » PG&E said in a… PG&E said in a statement, "With all major wildfire claims now on a path to be resolved and the total amount of wildfire liabilities determined, PG&E will now amend and finalize its Plan, which will satisfy all wildfire claims in accordance with Assembly Bill 1054 and otherwise comply with all requirements of the Bankruptcy Code. The company remains on track to obtain regulatory approval and Bankruptcy Court confirmation of its Plan in advance of the June 30, 2020, statutory deadline set by AB 1054 for participation in the state's go-forward wildfire fund. In addition, PG&E has received over $12 billion of equity backstop commitments to support the settlement and its Plan." 03/08/13 Wedge Partners 03/08/13 Credit Suisse 03/06/13 Citigroup 03/06/13 Barclays See Street Research during your Free Trial	07 Jan

Events

Earnings calls, analyst events, roadshows and more

NNVC
Today at 10:00

NanoViricides, Inc. Firm Sponsored Meetings

700 E Main Street, Stamford, CT
INCY
Today at 19:00

Incyte Firm Sponsored Meetings

HUB 925--7594 West Sand Lake Road, Orlando, FL
MGTA
Today at 20:30

Magenta Therapeutics Firm Sponsored Meetings

Hyatt Regency Orlando, Orlando, FL
ALPN ...
Tomorrow at 00:00

2019 ASH Annual Meeting Conferences

Orange County Convention Center, Orlando, FL
RUHN
Tomorrow at 00:00

Ruhnn Firm Sponsored Meetings

West Coast
Tomorrow at 00:00

Biotechnology--Dinner Industry Meetings

Orlando, FL
Tomorrow at 00:00

Biotechnology--Luncheon Industry Meetings

Orlando, FL
SRRA
Tomorrow at 07:00

Sierra Oncology Firm Sponsored Meetings

Hyatt Regency--9801 International Dr--Bayhill 33 Meeting Rm, Orlando, FL
GBT
Tomorrow at 12:45

Global Blood Therapeutics Firm Sponsored Meetings
BMY
Tomorrow at 20:00

Bristol-Myers - BMY Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	ELF X ELF e.l.f. Beauty Block Trade Managers: Morgan Stanley Priced at: $15.90 3.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial AER X AER AerCap Spot Secondary Managers: Citi Priced at: $60.00 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CWEN X CWEN Clearway Energy Spot Secondary Managers: RBC Capital Priced at: $18.70 5.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FSV X FSV FirstService Spot Secondary Managers: BMO Capital & TD Securities Priced at: $92.50 2.165M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	ARWR X ARWR Arrowhead Secondary Managers: Goldman Sachs, Jefferies, Piper Jaffray & Cantor Fitzgerald, Baird, B. Riley FBR Priced at: $58.00 4M Shares ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: H.C. Wainwright Priced at: $2.50 5.125M Shares KOD X KOD Kodiak Sciences Secondary Managers: JPMorgan, Goldman Sachs & Jefferies Priced at: $46.00 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRAY X VRAY ViewRay Secondary Managers: Piper Jaffray Priced at: $3.13 41.55M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CNNE X CNNE Cannae Holdings Spot Secondary Managers: BofA/Merrill & Stephens Priced at: $33.00 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RLMD X RLMD Relmada Therapeutics Spot Secondary Managers: Jefferies, SVB Leerink & Guggenheim Priced at: $30.00 3.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RVNC X RVNC Revance Spot Secondary Managers: Cowen, Piper Jaffray & Stifel Priced at: $17.00 6.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	LMPX X LMPX LMP Automotive IPO Managers: ThinkEquity Priced at: $5.00 2.3M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CCC X CCC Clarivate Analytics Secondary Managers: Citi & Goldman Sachs Priced at: $17.25 43.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial IMMU X IMMU Immunomedics Secondary Managers: Goldman Sachs, BofA/Merrill, Cowen & Jefferies Priced at: $17.50 14.29M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TUFN X TUFN Tufin Secondary Managers: JPMorgan, Barclays & Jefferies, Oppenheimer, Baird, Piper Jaffray, Stifel, William Blair Priced at: $17.00 4.28M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ARDX X ARDX Ardelyx Spot Secondary Managers: Citi, Cowen, SVB Leerink & Piper Jaffray Priced at: $6.25 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MLND X MLND Millendo Therapeutics Spot Secondary Managers: Citi & SVB Leerink Priced at: $6.00 4.167M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NJR X NJR New Jersey Resources Spot Secondary Managers: Wells Fargo & JPMorgan, BBNT, TD Securities, Goldman Sachs, Janney Montgomery Scott, Siebert Williams Priced at: $41.25 5.7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OMER X OMER Omeros Spot Secondary Managers: Cantor Fitzgerald Priced at: $13.10 3.816M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RC X RC Ready Capital Spot Secondary Managers: Morgan Stanley, UBS, Wells Fargo & Keefe Bruyette Priced at: $15.58 6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial WHF X WHF WhiteHorse Finance Spot Secondary Managers: Raymond James, Keefe Bruyette & Deutsche Bank, Ladenburg, Oppenheimer, B. Riley FBR, National Securities Priced at: $13.83 2.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	DT X DT Dynatrace Secondary Managers: Goldman Sachs, JPMorgan, Citi, RBC Capital, BofA/Merrill, Barclays, UBS & Jefferies, Canaccord, WBLR BTIG, JMP Securities, KeyBanc, Raymond James, Academy Securities Priced at: $24.75 27.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVRI X EVRI Everi Holdings Secondary Managers: Jefferies, Stifel, Craig-Hallum & Raymond James, SunTrust Priced at: $11.25 10M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial GDS X GDS GDS Holdings Secondary Managers: JPMorgan, RBC Capital & BofA/Merrill, Haitong International Priced at: $45.50 5.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLUG X PLUG Plug Power Secondary Managers: Morgan Stanley & Barclays Priced at: $2.75 40M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TTEC X TTEC TTEC Holdings Secondary Managers: BofA/Merrill, Morgan Stanley, Cowen, Craig-Hallum & William Blair, Northland, HSBC Priced at: $36.50 3M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CATC X CATC Cambridge Bancorp Spot Secondary Managers: Keefe Bruyette Priced at: $73.00 479K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $13.25 11.18M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVOP X EVOP EVO Payments Spot Secondary Managers: JPMorgan & Barclays Priced at: $27.60 4.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ISEE X ISEE IVERIC bio Spot Secondary Managers: Cowen Priced at: $4.00 6.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

HCA Healthcare's Foster sells 19,477 common shares

TODAY'S FREE FLY STORIES

Get Full Fly Access